Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03983525 · ClinicalTrials.gov registry record · NA
The Effect of Gojiberry Intake (Lycium Barbarium) on Macular Function
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT03983525: Completed NA study, sponsored by University of California, Davis.
NCT03983525 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03983525, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
Objective: To evaluate the effects of goji berry intake for three months on macular pigment ocular density (MPOD) between 45 and 65 years old. Specific Aims: Determine if goji berry intake for 90 days, 5 times per week, will: * result in favorable changes in macular pigment optical density (MPOD), as measured using heterochromatic flicker photometry (HFP), in adults aged from 45 to 65 years old. * impact the carotenoid distribution in the skin. * will change the fermentation capacity of the gut microbiota. The investigators hypothesize that the intake of 28 grams of goji berry for 90 days, 5 days per week will significantly increase MPOD after three months, compared to baseline values. In contrast, the investigators hypothesize that a dietary supplement of lutein and zeaxanthin will not alter MPOD.
Primary Outcome
MPOD measurement - MPOD will be assessed by the psychophysical method of HFP technology (Macular Metrics, Providence, RI). Participants will watch a 20 minutes long video of a description of HFP. After adapting to the dark for seven minutes, participants will be asked to rest their head on a chin rest and look at a blue background field for three minutes. Prior to each test, the light intensity from each wavelength will be calibrated with a photodiode. The flicker frequency is selected for each
Interventions
- DIETARY_SUPPLEMENT Goji berry
- DIETARY_SUPPLEMENT Lutein + zeaxanthin supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-06-10 |
| Est. Completion | 2020-06-15 |
| Phase | NA |
What the finished NCT03983525 record still lists
NCT03983525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Goji berry is the first listed.
NCT03983525 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03983525 about?
NCT03983525 is a clinical study titled "The Effect of Gojiberry Intake (Lycium Barbarium) on Macular Function". Objective: To evaluate the effects of goji berry intake for three months on macular pigment ocular density (MPOD) between 45 and 65 years old. Specific Aims: Determine if goji berry intake for 90 days, 5 times per week, will: * result in favorable changes in macular pigment optical density (MPOD)...
What is the current status of trial NCT03983525?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2019-06-10. Estimated completion is 2020-06-15.
What interventions are being tested in trial NCT03983525?
The interventions under investigation include: Goji berry (DIETARY_SUPPLEMENT), Lutein + zeaxanthin supplementation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03983525?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03983525's enrollment target sits among peer trials
31 1592nd of 2000 higher than 408 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI